We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Transluminal Angioplasty Stenting Improves Blood Flow in Extremities

By HospiMedica International staff writers
Posted on 14 Aug 2012
A new study suggests that patients with critical limb ischemia (CLI) may find relief through a previously unproven therapy, infrapopliteal artery stent implantation.

Researchers at the Prairie Education & Research Cooperative (Springfield, IL, USA) conducted a study that followed 120 patients who underwent primary infrapopliteal nickel-titanium (nitinol) stent deployment via percutaneous transluminal angioplasty (PTA) as part of the multicenter Xpert Nitinol Stenting for Critically IschEmic Lower Limbs (XCELL) trial. More...
The trial evaluated the safety and effectiveness of the Xpert self-expanding nitinol stent, a product of Abbott Vascular (Redwood City, CA, USA).

In all, 140 limbs in the 120 Rutherford Class 4-6 subjects with infrapopliteal lesions of 4-15 cm in length were treated with 212 implanted devices. The primary endpoint was 12-month amputation-free survival (AFS); secondary endpoints included limb salvage, target lesion revascularization (TLR), 6- month angiographic patency, and 6- and 12-month outcomes of wound healing and pain relief.

The results showed that despite a 6-month binary stent restenosis rate of 68.5%, the average 12-month AFS rate was 78.3%. The 12-month freedom from major amputation rate and clinically driven TLR were 89.6% and 70.1%, respectively, and the 6- and 12-month complete wound-healing rates were 49.0% and 54.4%, respectively. Rutherford class 4 patients had significant pain relief through 12-months. The study was published ahead of print on May 17, 2012, in Catheterization and Cardiovascular Interventions.

“Our XCELL trial findings confirm that infrapopliteal nitinol stenting is safe and effective in treating CLI patients,” concluded lead author Krishna Rocha-Singh, MD, and colleagues. “While there were a few major adverse events, such as death, heart attack, or major amputation that occurred in the first 30 days, at the first year postprocedure, limb preservation, wound healing and pain relief rates were excellent.”

CLI affects close to 30 million people in Europe and North America, with most experiencing pain and ulcers with or without gangrene in the legs. Previous research shows amputation rates are as high as 40% in CLI patients in the first year following their diagnosis, with mortality rates approaching 20%. Moreover, an estimated 160,000 amputations due to peripheral artery disease (PAD) are performed each year in the United States alone, of which a 25% reduction could save almost USD 30 billion in health care costs.

Related Links:

Prairie Education & Research Cooperative
Abbott Vascular



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.